Zobrazeno 1 - 10
of 27
pro vyhledávání: '"S. G. Kanorskiy"'
Autor:
S. G. Kanorskiy, V. P. Pavlovets
Publikováno v:
Инновационная медицина Кубани, Vol 0, Iss 1, Pp 37-44 (2024)
Background: As the survival of patients with malignant neoplasms is improving, the urgent need for cardioprotective agents to counteract toxic effects of chemotherapy is growing.Objective: To compare the cardioprotective efficacy of sacubitril/valsar
Externí odkaz:
https://doaj.org/article/abea9fca0f99412d934407b09ee74960
Autor:
S. G. Kanorskiy
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 59-67 (2021)
Arterial hypertension was one of the most common comorbidities associated with a high risk of death in hospitalized patients with COVID-19. Patients with hypertension are routinely and according to standards treated with angiotensinconverting enzyme
Externí odkaz:
https://doaj.org/article/3ddc934b2b24451fa7a7b1294fef837a
Autor:
S. G. Kanorskiy, V. P. Pavlovets
Publikováno v:
Медицинский совет, Vol 0, Iss 16, Pp 42-48 (2019)
Objective. Comparison of the cardioprotective efficacy of valsartan/sacubitril and candesartan in women with heart failure (HF) and an initially reduced left ventricular ejection fraction receiving breast cancer chemotherapy.Material and methods. A p
Externí odkaz:
https://doaj.org/article/eb3aa7b2070c420d914421cf81fd0851
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 7, Iss 6, Pp 752-756 (2016)
Aim. To estimate metoprolol succinate effect on regulatory and adaptive status (RAS) of patients with сhronic heart failure (CHF) functional class (FC) I and arterial hypertension (HT) I-II stages. Material and methods. 51 patients with CHF FC I and
Externí odkaz:
https://doaj.org/article/f5ed29d6cf054882b459852270fa65cb
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 8, Iss 4, Pp 526-530 (2015)
Aim. To assess effects of quinapril on the regulatory-adaptive status (RAS) in patients with chronic heart failure (CHF) NYHA class 1 and arterial hypertension (HT). Material and methods. Patients (n=49) with CHF NYHA class I and HT stage I–II (25
Externí odkaz:
https://doaj.org/article/64dea749af164f609ecdee15683dbb49
Autor:
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 551-556 (2015)
Disadvantages of vitamin K antagonist warfarin and the benefits of new anticoagulants, including dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors that influence the choice of dabigatran dose
Externí odkaz:
https://doaj.org/article/5cc44adbbae74f068d1d2dfd33f7451a
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 10, Iss 2, Pp 69-74 (2011)
Aim. To assess the effectiveness of ivabradine-including therapy, as well as the effects of ivabradine on regulatoryadaptive status (RAS), in patients with chronic heart failure (CHF), Functional Class (FC) III. Material and methods. The study includ
Externí odkaz:
https://doaj.org/article/874a6903ebf84a22ba0af273b43009fb
Autor:
S. G. Kanorskiy
Publikováno v:
Meditsinskiy sovet = Medical Council. :44-51
Chronic heart failure (CHF) is one of the most important problems in clinical cardiology due to high morbidity, frequent hospitalizations and poor prognosis of patients. Quite unexpectedly, sodium-glucose cotransporter type 2 (SGLT2i) inhibitors dapa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfaac165f9cb5de3782ebb7e3df0c51b
https://doi.org/10.21518/2079-701x-2022-16-17-44-51
https://doi.org/10.21518/2079-701x-2022-16-17-44-51
Autor:
Y V Borisenko, S G Kanorskiy
Publikováno v:
Kardiologiia. 17:85-89
Chronic heart failure with preserved ejection fraction (HFpEF) accounts for about 50% of cases of heart failure, but pharmacotherapy that improves its outcomes has not been developed. The proven principle of improving outcomes in patients with chroni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07160ea22060b1a75cc1731b4e91c5d5
https://doi.org/10.18087/cardio.2018.6.10154
https://doi.org/10.18087/cardio.2018.6.10154
Autor:
S G Kanorskiy
Publikováno v:
Kardiologiia. 17:4-10
Conducting anticoagulant therapy for atrial fibrillation, combined with diabetes mellitus and/or chronic kidney disease, can create certain difficulties for practicing doctors due to a simultaneous increase in the risk of thromboembolic and hemorrhag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d683e13b048e265c4ed837b13e5b2b53
https://doi.org/10.18087/cardio.2469
https://doi.org/10.18087/cardio.2469